nodes	percent_of_prediction	percent_of_DWPC	metapath
Metaxalone—Leukopenia—Altretamine—ovarian cancer	0.0541	0.0541	CcSEcCtD
Metaxalone—Haemolytic anaemia—Chlorambucil—ovarian cancer	0.0395	0.0395	CcSEcCtD
Metaxalone—Haemolytic anaemia—Melphalan—ovarian cancer	0.0344	0.0344	CcSEcCtD
Metaxalone—Anaphylactoid reaction—Topotecan—ovarian cancer	0.0328	0.0328	CcSEcCtD
Metaxalone—Dizziness—Altretamine—ovarian cancer	0.0326	0.0326	CcSEcCtD
Metaxalone—Vomiting—Altretamine—ovarian cancer	0.0314	0.0314	CcSEcCtD
Metaxalone—Nausea—Altretamine—ovarian cancer	0.0293	0.0293	CcSEcCtD
Metaxalone—Jaundice—Chlorambucil—ovarian cancer	0.0268	0.0268	CcSEcCtD
Metaxalone—Jaundice—Melphalan—ovarian cancer	0.0234	0.0234	CcSEcCtD
Metaxalone—Leukopenia—Chlorambucil—ovarian cancer	0.0192	0.0192	CcSEcCtD
Metaxalone—Leukopenia—Topotecan—ovarian cancer	0.0171	0.0171	CcSEcCtD
Metaxalone—Leukopenia—Melphalan—ovarian cancer	0.0168	0.0168	CcSEcCtD
Metaxalone—Anaphylactic shock—Topotecan—ovarian cancer	0.0156	0.0156	CcSEcCtD
Metaxalone—Anaphylactic shock—Melphalan—ovarian cancer	0.0153	0.0153	CcSEcCtD
Metaxalone—Leukopenia—Vinorelbine—ovarian cancer	0.0146	0.0146	CcSEcCtD
Metaxalone—Anaphylactic shock—Vinorelbine—ovarian cancer	0.0134	0.0134	CcSEcCtD
Metaxalone—Hypersensitivity—Chlorambucil—ovarian cancer	0.0129	0.0129	CcSEcCtD
Metaxalone—Pruritus—Chlorambucil—ovarian cancer	0.0124	0.0124	CcSEcCtD
Metaxalone—Jaundice—Docetaxel—ovarian cancer	0.0116	0.0116	CcSEcCtD
Metaxalone—Hypersensitivity—Topotecan—ovarian cancer	0.0115	0.0115	CcSEcCtD
Metaxalone—Hypersensitivity—Melphalan—ovarian cancer	0.0113	0.0113	CcSEcCtD
Metaxalone—Vomiting—Chlorambucil—ovarian cancer	0.0111	0.0111	CcSEcCtD
Metaxalone—Pruritus—Topotecan—ovarian cancer	0.011	0.011	CcSEcCtD
Metaxalone—Pruritus—Melphalan—ovarian cancer	0.0108	0.0108	CcSEcCtD
Metaxalone—Tension—Paclitaxel—ovarian cancer	0.0108	0.0108	CcSEcCtD
Metaxalone—Anaphylactoid reaction—Epirubicin—ovarian cancer	0.0108	0.0108	CcSEcCtD
Metaxalone—Nervousness—Paclitaxel—ovarian cancer	0.0107	0.0107	CcSEcCtD
Metaxalone—Nausea—Chlorambucil—ovarian cancer	0.0104	0.0104	CcSEcCtD
Metaxalone—Dizziness—Topotecan—ovarian cancer	0.0103	0.0103	CcSEcCtD
Metaxalone—Anaphylactoid reaction—Doxorubicin—ovarian cancer	0.00999	0.00999	CcSEcCtD
Metaxalone—Vomiting—Topotecan—ovarian cancer	0.00992	0.00992	CcSEcCtD
Metaxalone—Leukopenia—Paclitaxel—ovarian cancer	0.00985	0.00985	CcSEcCtD
Metaxalone—Rash—Topotecan—ovarian cancer	0.00984	0.00984	CcSEcCtD
Metaxalone—Hypersensitivity—Vinorelbine—ovarian cancer	0.00984	0.00984	CcSEcCtD
Metaxalone—Dermatitis—Topotecan—ovarian cancer	0.00983	0.00983	CcSEcCtD
Metaxalone—Headache—Topotecan—ovarian cancer	0.00978	0.00978	CcSEcCtD
Metaxalone—Vomiting—Melphalan—ovarian cancer	0.00972	0.00972	CcSEcCtD
Metaxalone—Rash—Melphalan—ovarian cancer	0.00964	0.00964	CcSEcCtD
Metaxalone—Dermatitis—Melphalan—ovarian cancer	0.00963	0.00963	CcSEcCtD
Metaxalone—Pruritus—Vinorelbine—ovarian cancer	0.00945	0.00945	CcSEcCtD
Metaxalone—Nausea—Topotecan—ovarian cancer	0.00927	0.00927	CcSEcCtD
Metaxalone—Nausea—Melphalan—ovarian cancer	0.00908	0.00908	CcSEcCtD
Metaxalone—Anaphylactic shock—Paclitaxel—ovarian cancer	0.00898	0.00898	CcSEcCtD
Metaxalone—Dizziness—Vinorelbine—ovarian cancer	0.00883	0.00883	CcSEcCtD
Metaxalone—Vomiting—Vinorelbine—ovarian cancer	0.00849	0.00849	CcSEcCtD
Metaxalone—Rash—Vinorelbine—ovarian cancer	0.00842	0.00842	CcSEcCtD
Metaxalone—Dermatitis—Vinorelbine—ovarian cancer	0.00841	0.00841	CcSEcCtD
Metaxalone—Headache—Vinorelbine—ovarian cancer	0.00836	0.00836	CcSEcCtD
Metaxalone—Leukopenia—Docetaxel—ovarian cancer	0.00835	0.00835	CcSEcCtD
Metaxalone—Drowsiness—Epirubicin—ovarian cancer	0.00805	0.00805	CcSEcCtD
Metaxalone—Somnolence—Paclitaxel—ovarian cancer	0.00798	0.00798	CcSEcCtD
Metaxalone—Nausea—Vinorelbine—ovarian cancer	0.00793	0.00793	CcSEcCtD
Metaxalone—Jaundice—Epirubicin—ovarian cancer	0.00785	0.00785	CcSEcCtD
Metaxalone—Anaphylactic shock—Docetaxel—ovarian cancer	0.00761	0.00761	CcSEcCtD
Metaxalone—Drowsiness—Doxorubicin—ovarian cancer	0.00745	0.00745	CcSEcCtD
Metaxalone—Jaundice—Doxorubicin—ovarian cancer	0.00726	0.00726	CcSEcCtD
Metaxalone—Somnolence—Docetaxel—ovarian cancer	0.00677	0.00677	CcSEcCtD
Metaxalone—Hypersensitivity—Paclitaxel—ovarian cancer	0.00662	0.00662	CcSEcCtD
Metaxalone—Pruritus—Paclitaxel—ovarian cancer	0.00635	0.00635	CcSEcCtD
Metaxalone—Tension—Epirubicin—ovarian cancer	0.00617	0.00617	CcSEcCtD
Metaxalone—Nervousness—Epirubicin—ovarian cancer	0.00611	0.00611	CcSEcCtD
Metaxalone—Dizziness—Paclitaxel—ovarian cancer	0.00594	0.00594	CcSEcCtD
Metaxalone—Tension—Doxorubicin—ovarian cancer	0.00571	0.00571	CcSEcCtD
Metaxalone—Vomiting—Paclitaxel—ovarian cancer	0.00571	0.00571	CcSEcCtD
Metaxalone—Rash—Paclitaxel—ovarian cancer	0.00566	0.00566	CcSEcCtD
Metaxalone—Dermatitis—Paclitaxel—ovarian cancer	0.00566	0.00566	CcSEcCtD
Metaxalone—Nervousness—Doxorubicin—ovarian cancer	0.00565	0.00565	CcSEcCtD
Metaxalone—Leukopenia—Epirubicin—ovarian cancer	0.00563	0.00563	CcSEcCtD
Metaxalone—Headache—Paclitaxel—ovarian cancer	0.00563	0.00563	CcSEcCtD
Metaxalone—Hypersensitivity—Docetaxel—ovarian cancer	0.00561	0.00561	CcSEcCtD
Metaxalone—Pruritus—Docetaxel—ovarian cancer	0.00539	0.00539	CcSEcCtD
Metaxalone—Nausea—Paclitaxel—ovarian cancer	0.00533	0.00533	CcSEcCtD
Metaxalone—Leukopenia—Doxorubicin—ovarian cancer	0.00521	0.00521	CcSEcCtD
Metaxalone—Anaphylactic shock—Epirubicin—ovarian cancer	0.00513	0.00513	CcSEcCtD
Metaxalone—Dizziness—Docetaxel—ovarian cancer	0.00503	0.00503	CcSEcCtD
Metaxalone—Vomiting—Docetaxel—ovarian cancer	0.00484	0.00484	CcSEcCtD
Metaxalone—Rash—Docetaxel—ovarian cancer	0.0048	0.0048	CcSEcCtD
Metaxalone—Dermatitis—Docetaxel—ovarian cancer	0.0048	0.0048	CcSEcCtD
Metaxalone—Headache—Docetaxel—ovarian cancer	0.00477	0.00477	CcSEcCtD
Metaxalone—Anaphylactic shock—Doxorubicin—ovarian cancer	0.00475	0.00475	CcSEcCtD
Metaxalone—Somnolence—Epirubicin—ovarian cancer	0.00456	0.00456	CcSEcCtD
Metaxalone—Nausea—Docetaxel—ovarian cancer	0.00452	0.00452	CcSEcCtD
Metaxalone—Somnolence—Doxorubicin—ovarian cancer	0.00422	0.00422	CcSEcCtD
Metaxalone—Hypersensitivity—Epirubicin—ovarian cancer	0.00378	0.00378	CcSEcCtD
Metaxalone—Pruritus—Epirubicin—ovarian cancer	0.00363	0.00363	CcSEcCtD
Metaxalone—Hypersensitivity—Doxorubicin—ovarian cancer	0.0035	0.0035	CcSEcCtD
Metaxalone—Dizziness—Epirubicin—ovarian cancer	0.0034	0.0034	CcSEcCtD
Metaxalone—Pruritus—Doxorubicin—ovarian cancer	0.00336	0.00336	CcSEcCtD
Metaxalone—Vomiting—Epirubicin—ovarian cancer	0.00326	0.00326	CcSEcCtD
Metaxalone—Rash—Epirubicin—ovarian cancer	0.00324	0.00324	CcSEcCtD
Metaxalone—Dermatitis—Epirubicin—ovarian cancer	0.00323	0.00323	CcSEcCtD
Metaxalone—Headache—Epirubicin—ovarian cancer	0.00322	0.00322	CcSEcCtD
Metaxalone—Dizziness—Doxorubicin—ovarian cancer	0.00314	0.00314	CcSEcCtD
Metaxalone—Nausea—Epirubicin—ovarian cancer	0.00305	0.00305	CcSEcCtD
Metaxalone—Vomiting—Doxorubicin—ovarian cancer	0.00302	0.00302	CcSEcCtD
Metaxalone—Rash—Doxorubicin—ovarian cancer	0.003	0.003	CcSEcCtD
Metaxalone—Dermatitis—Doxorubicin—ovarian cancer	0.00299	0.00299	CcSEcCtD
Metaxalone—Headache—Doxorubicin—ovarian cancer	0.00298	0.00298	CcSEcCtD
Metaxalone—Nausea—Doxorubicin—ovarian cancer	0.00282	0.00282	CcSEcCtD
